<DOC>
	<DOCNO>NCT00648648</DOCNO>
	<brief_summary>This study investigate MK1775 alone combination one follow three drug : gemcitabine , cisplatin , carboplatin patient advance solid tumor . The purpose study test safety tolerability MK1775 alone combination , find maximum tolerate dose ( MTD ) MK1775 monotherapy combination therapy .</brief_summary>
	<brief_title>A Dose Escalation Study MK1775 Combination With Either Gemcitabine , Cisplatin , Carboplatin Adults With Advanced Solid Tumors ( MK-1775-001 AM7 )</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Subject must histologically confirm metastatic locally advanced solid tumor , progress despite standard therapy , standard therapy exist Subject least 18 year old Subject must performance status &lt; =1 ECOG Performance Scale Female subject must pregnant Subject chemotherapy , radiotherapy , biological therapy within 4 week prior enter study recover adverse event due agent give 4 week earlier Subject participate participate study investigational compound device within 30 day Subjects active CNS metastasis and/or carcinomatous meningitis exclude . However , subject CNS metastasis complete course therapy would eligible study provide clinically stable 1 month prior entry Subject primary central nervous system tumor Subject allergic component combination study therapy analog Participant prescription nonprescription drug product know metabolized CYP3A4 discontinue prior Day 1 dose withheld throughout study 2 week last dose study medication . Medications particular concern inhibitor CYP3A4 ( azole antifungal [ ketoconazole , itraconazole ] , macrolide antibiotic [ erythromycin , clarithromycin ] , cimetidine , aprepitant , HIV protease inhibitor , nefrazodone , follow inducer CYP3A4 : phenytoin , barbiturates rifampicin , substrates CYP3A4 include statin ( lovastatin , simvastatin ) , midazolam , terfenadine , astemizole , cisapride Subject regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse Subject pregnant breastfeeding , expect get pregnant time study ongoing Subject ( HIV ) positive Subject history Hepatitis B C Subject symptomatic ascites pleural effusion . A subject clinically stable follow treatment condition eligible Subject must prior radiation therapy 30 % bone marrow must recover least 3 week hematologic toxicity prior radiotherapy Subject prior stem cell bone marrow transplant Subject receive 4 prior cytotoxic chemotherapy regimens Participant history suggestive LiFraumeni Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>